Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Developing and Characterizing the Anti-Tumor Efficacy of a Tri-Specific CAR T Cell Targeting CD19, CD20 and CD22

Michael Sheng, Logan Vick, Craig Collins, Ryan Nielsen, Joseph M Tuscano, Rimas J Orentas, Ying Xiong, William Murphy

Blood (2024) 144 (Supplement 1): 7128.

https://doi.org/10.1182/blood-2024-199366

Published: 2024

Journal Articles

Optimization of Lentiviral ß-Globin Vectors in a Forward Orientation to Enhance Therapeutic Effectiveness for Sickle Cell Disease

Jennifer Okalova, Jordan Shields Alexander, Christopher Chambliss, Zhongyu Zhu, Yanping Xie, Matthew Addington-Hall, Oxana Slessareva, Tony Luo, Beatrix Ferencz, Ibeawuchi Oparaocha, Naoya Uchida, John F. Tisdale, Boro Dropulic, H. Trent Spencer, Rimas J Orentas, David R Archer

Blood (2023) 142 (Supplement 1): 5002.

https://doi.org/10.1182/blood-2023-187506

Published: 2023

Journal Articles

CAR-T Cell Therapy of Solid Tumors Invokes an Expanded Set of Myeloid Cells in an Orthotopic Tumor Model for Rhabdomyosarcoma

Peter Sullivan, Yue Zhang, Virginia Hoglund, Sophie Jamet, Isela J Garcia, Rimas J Orentas

Blood (2022) 140 (Supplement 1): 10277–10278.

https://doi.org/10.1182/blood-2022-164779

Published: 2022

Journal Articles

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Corinne Summers, Blake Baxter, Colleen Annesley, Jason Yokoyama, Stephanie Rhea, Wenjun Huang, Ashley Wilson, Julie R. Park, Rimas J Orentas, Michael C. Jensen, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 403.

https://doi.org/10.1182/blood-2021-147928

Published: 2021

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Paolo F Caimi, MD, Ashish Sharma, Patricio Rojas, MD, Seema Patel, PharmD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Andrew Worden, Michael Kadan, Michael Maschan, MD PhD, Rimas J Orentas, PhD, Boro Dropulic, PhDMBA, Rafick Sekaly, Marcos de Lima, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-143114

Published: 2020

Journal Articles

CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers

Lingyan Wang, PhDDVM, Yue Zhang, MS, Eden Anderson, BS, Rajesh Kumar, PhD, Adam J. Lamble, MD, Rimas J Orentas, PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134930

Published: 2020

Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2019) 134 (Supplement_1): 4465.

https://doi.org/10.1182/blood-2019-125328

Published: 2019

Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2018-99-117493

Published: 2018

Journal Articles

Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein

Haiying Qin, Monica Cho, Waleed Haso, Ling Zhang, Sarah K. Tasian, Htoo Zarni Oo, Gian Luca Negri, Yongshun Lin, Jizhong Zou, Barbara S. Mallon, Shannon Maude, David T. Teachey, David M. Barrett, Rimas J. Orentas, Mads Daugaard, Poul H. B. Sorensen, Stephan A. Grupp, Terry J. Fry

Blood (2015) 126 (5): 629–639.

https://doi.org/10.1182/blood-2014-11-612903

Published: 2015

Includes: Supplemental data

Journal Articles

CD22-Targeted Chimeric Antigen Receptor (CAR) T Cells Containing The 4-1BB Costimulatory Domain Demonstrate Enhanced Persistence and Superior Efficacy Against B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Compared To Those Containing CD28

Waleed Haso, M.S, Haiying Qin, MS, Ling Zhang, Rimas J Orentas, PhD, Terry J Fry, MD

Blood (2013) 122 (21): 1431.

https://doi.org/10.1182/blood.V122.21.1431.1431

Published: 2013

Journal Articles

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

Haying Qin, Cho Monica, Waleed Haso, M.S., Ling Zhang, David M. Barrett, MD/PhD, Rimas J Orentas, PhD, Stephan A. Grupp, MD, PhD, Terry J Fry, MD

Blood (2013) 122 (21): 2665.

https://doi.org/10.1182/blood.V122.21.2665.2665

Published: 2013

Journal Articles

Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells

Adrienne H. Long, Rimas J. Orentas, PhD, Crystal L. Mackall, MD

Blood (2013) 122 (21): 192.

https://doi.org/10.1182/blood.V122.21.192.192

Published: 2013

Journal Articles

Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

Hua Zhang, Irena Maric, Michael J. DiPrima, Javed Khan, Rimas J. Orentas, Rosandra N. Kaplan, Crystal L. Mackall

Blood (2013) 122 (7): 1105–1113.

https://doi.org/10.1182/blood-2012-08-449413

Published: 2013

Includes: Supplemental data

Journal Articles

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance M. Yuan, Ira H. Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas

Blood (2013) 121 (7): 1165–1174.

https://doi.org/10.1182/blood-2012-06-438002

Published: 2013

Includes: Supplemental data

Journal Articles

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Waleed Haso, M.S., Daniel W. Lee, III, MD, Ira Pastan, MD, Dimiter S. Dimitrov, Ph.D, Crystal L Mackall, MD, Rimas J Orentas, PhD

Blood (2012) 120 (21): 2611.

https://doi.org/10.1182/blood.V120.21.2611.2611

Published: 2012

Journal Articles

ALL Xenografts Reveal the Importance of Anti-CD19-Chimeric Antigen Receptor Cell Dose, Cell Persistence and Surprising Antitumor Activity of CD4+ Anti-CD19-CAR T Cells in Eradicating Pediatric Acute Lymphocytic Leukemia In Vivo

Daniel W. Lee, III, MD, James N Kochenderfer, Rimas J Orentas, PhD, Elizabeth G. Gardner, B.S., Crystal L Mackall, MD

Blood (2011) 118 (21): 574.

https://doi.org/10.1182/blood.V118.21.574.574

Published: 2011

Journal Articles

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Rimas J Orentas, PhD, Waleed Haso, B.S., Richard A. Morgan, Ira Pastan, MD, Crystal L Mackall, MD

Blood (2011) 118 (21): 4313.

https://doi.org/10.1182/blood.V118.21.4313.4313

Published: 2011

Journal Articles

Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor

Daniel W. Lee, MD, James N Kochenderfer, Christoph Rader, PhD, Rimas J Orentas, PhD, Crystal L Mackall, MD

Blood (2010) 116 (21): 3262.

https://doi.org/10.1182/blood.V116.21.3262.3262

Published: 2010

Journal Articles

4-1BBL-Expressing aAPCs Attenuate IL-15-Induced NK Cell Expansion and Cytokine Production In Vitro but Induce NK Cell-Mediated Gvhd In Vivo

Christian M. Capitini, MD, Joanna L. Meadors, BS, Monica M. Cho, Rimas J. Orentas, PhD, Crystal L. Mackall, MD, Terry J. Fry, MD

Blood (2010) 116 (21): 2536.

https://doi.org/10.1182/blood.V116.21.2536.2536

Published: 2010

NARROW

Developing and Characterizing the Anti-Tumor Efficacy of a Tri-Specific CAR T Cell Targeting CD19, CD20 and CD22

Optimization of Lentiviral ß-Globin Vectors in a Forward Orientation to Enhance Therapeutic Effectiveness for Sickle Cell Disease

CAR-T Cell Therapy of Solid Tumors Invokes an Expanded Set of Myeloid Cells in an Orthotopic Tumor Model for Rhabdomyosarcoma

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein

CD22-Targeted Chimeric Antigen Receptor (CAR) T Cells Containing The 4-1BB Costimulatory Domain Demonstrate Enhanced Persistence and Superior Efficacy Against B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Compared To Those Containing CD28

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells

Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

ALL Xenografts Reveal the Importance of Anti-CD19-Chimeric Antigen Receptor Cell Dose, Cell Persistence and Surprising Antitumor Activity of CD4+ Anti-CD19-CAR T Cells in Eradicating Pediatric Acute Lymphocytic Leukemia In Vivo

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor

4-1BBL-Expressing aAPCs Attenuate IL-15-Induced NK Cell Expansion and Cytokine Production In Vitro but Induce NK Cell-Mediated Gvhd In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only